Compare Logitech International SA (LOGI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs TG Therapeutics Inc — how do they compare? Logitech International SA trades at $101.7 (market cap $14.65B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Logitech International SA is the larger of the two by market cap, and Logitech International SA pays a 1.67% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LOGI | TGTX | |
|---|---|---|
Market Cap | $14.65B | $8.26B |
Sector | Technology | Health |
52-Week High | $126.69 | $59.06 |
52-Week Low | $85.84 | $26.39 |
Enterprise Value | $13.00B | $8.50B |
Dividend Yield | 1.67% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
